Adrafinil vs NSI-189

Mechanism

Inactive prodrug that is hepatically metabolized to modafinil (via hepatic amidase enzymes) and its inactive acid metabolite modafinilic acid. The active metabolite modafinil then exerts its effects as a DAT inhibitor with downstream orexinergic, histaminergic, and noradrenergic activation. Conversion is incomplete — approximately 33-50% of adrafinil is converted to modafinil, with the remainder forming inactive metabolites. The hepatic first-pass metabolism means onset is delayed (60-90 minutes vs. 30-60 minutes for modafinil).

Standard Dosing

300-600 mg once daily (for educational context — unregulated prodrug of a prescription medication)

Timing

Early morning on an empty stomach for faster hepatic conversion. Onset delayed 60-90 minutes. Avoid afternoon/evening dosing due to long effective duration.

Cycle Duration

Short-term or intermittent use strongly preferred. Avoid continuous daily use exceeding 3 months without liver function monitoring.

Side Effects

• All modafinil side effects apply
• Elevated liver enzymes (ALT/AST)
• Potential hepatotoxicity with chronic use
• Skin reactions
• GI distress (more common than with modafinil due to hepatic metabolism)

Contraindications

• Hepatic impairment of any severity
• Concurrent hepatotoxic medication
• All contraindications for modafinil apply (cardiac conditions, anxiety disorders, pregnancy)
• History of liver disease or elevated liver enzymes

Best Stacking Partners

Mechanism

Benzylpiperizine-aminopyridine compound that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and increases hippocampal volume in vivo. Mechanism is independent of serotonin or norepinephrine reuptake inhibition — fundamentally distinct from traditional antidepressants. Activates the TrkB receptor (BDNF receptor) and downstream Akt/PI3K signaling pathways to promote synaptic plasticity, long-term potentiation, and neuronal survival. Enhances BDNF expression in hippocampal subregions critical for memory consolidation and mood regulation. Originally developed as ALTO-100 (Alto Neuroscience) for treatment-resistant depression with cognitive impairment.

Standard Dosing

40 mg once daily (for educational context — investigational compound, not approved for any indication)

Timing

Once daily, time of day not definitively established from clinical data. With or without food.

Cycle Duration

Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable.

Side Effects

• Headache
• GI discomfort
• Dizziness
• Somnolence
• Dry mouth
• Generally well-tolerated in Phase 1b and Phase 2 trials

Contraindications

• Pregnancy and lactation (no safety data; neurogenic compounds carry theoretical teratogenic risk)
• History of brain tumors (neurogenic stimulation could theoretically promote growth — speculative)
• No regulatory approval for any indication — investigational use only

Best Stacking Partners